Full year results for the year ended 31 May 2026

Filtronic's profits and cash fell despite record contract wins and new facility claims.

What the company is saying

Filtronic frames its narrative around major contract wins, most notably a $62.5m SpaceX order, and emphasizes a successful transition to a new self-funded manufacturing facility with claimed production capacity exceeding £200m per annum. The announcement highlights diversification with new multi-year contracts in the US and Europe, and stresses a reduction in revenue concentration from its largest customer, now at 68% versus 83% previously. Management asserts confidence in meeting FY2027 market expectations and points to a strong order book covering approximately 90% of anticipated revenue, though no absolute figures are given. The tone is upbeat, focusing on strategic progress and future opportunities, while operational and financial headwinds are not directly addressed. Several forward-looking statements are made about growth, technology investment, and customer diversification, but these are not quantified.

What the data suggests

The audited results show revenue declined to £55.5m in FY2026 from £56.3m the prior year. Adjusted EBITDA dropped sharply to £11.3m from £17.0m, and operating profit fell to £4.0m from £13.4m. Profit before tax decreased to £3.8m from £13.4m, and profit for the year was £4.6m, down from £14.0m. Cash at bank at year end was £12.9m, a reduction from £14.5m, and net cash fell to £7.3m from £10.8m. Cash generated from operating activities also declined to £11.8m from £13.8m. The company secured large contracts, including $62.5m with SpaceX, $8.0m with a US customer, €7.0m with a European space client, and £13.4m with a European defence prime, but these have not yet translated into improved financial performance. The order book is described as covering 90% of FY2027 revenue expectations, but no absolute value or definition of 'market expectations' is disclosed. No segmental or geographic breakdowns, R&D, or capex figures are provided, limiting independent assessment of future growth claims.

Analysis

The announcement is upbeat, highlighting major contract wins, increased production capacity, and a strong order book. However, the underlying financials show a year-over-year decline in revenue, EBITDA, operating profit, and cash, which is not directly addressed in the narrative. While several realised milestones are disclosed (signed contracts, facility completion), many claims about future growth, customer diversification, and revenue weighting are forward-looking and lack precise quantification. The language around 'confidence in medium- and long-term opportunities' and 'supporting revenues in excess of £200m per annum' is aspirational, with no evidence that these levels are imminent or guaranteed. The order book coverage claim is positive but lacks an absolute value, making it difficult to assess its true significance. Overall, the tone is more positive than the measurable progress justifies, but the presence of signed contracts and disclosed profitability metrics prevents this from being classified as hype or a red flag.

Risk flags

• ●Financial performance deteriorated across all key metrics, with revenue, EBITDA, operating profit, and cash generation all declining year-over-year. This trend raises questions about the company's ability to convert contract wins into sustained profitability.
• ●Forward-looking claims about order book strength and meeting FY2027 expectations lack supporting detail, as no absolute order book value or explicit revenue/profit guidance is disclosed. This opacity limits investors' ability to gauge the credibility of management's outlook.
• ●The announcement emphasizes production capacity in excess of £200m per annum, but there is no evidence that demand or contracts are sufficient to utilize this capacity. Over-investment in fixed assets without corresponding revenue could pressure margins if growth does not materialize.

Bottom line

Despite winning its largest-ever contract and announcing new facility capacity, Filtronic's FY2026 results show declining revenue, profits, and cash. The company's upbeat messaging about future growth, customer diversification, and order book coverage is not matched by supporting data or improved financials. Key forward-looking statements are not quantified, and the lack of order book and capex detail makes it difficult to assess the likelihood of a near-term turnaround. Investors should focus on whether the new contracts and facility can drive actual revenue and margin growth in FY2027, as the current results do not demonstrate operational leverage or financial improvement. The most important takeaway is that headline contract wins have not yet translated into better bottom-line performance, and further disclosure is needed to validate the growth narrative.

Announcement summary

(AIM: FTC) Filtronic plc announced its audited full year results for the year ended 31 May 2026, reporting revenue of £55.5m and adjusted EBITDA of £11.3m. The company secured its largest single order to date, a $62.5m contract with SpaceX for next-generation Gallium Nitride ("GaN") E-band technology, and an $8.0m contract with a US-based customer for high-performance amplifier systems. Additional contract wins included a €7.0m agreement with a European space customer and a £13.4m contract with a leading European defence prime. Cash at bank at year end was £12.9m, with net cash of £7.3m and cash generated from operating activities of £11.8m. Filtronic completed its transition into a new self-funded Sedgefield headquarters and manufacturing facility, increasing production capacity to support revenues in excess of £200m per annum. The company projects that FY2027 revenue will be H2 weighted due to the transition between Gallium Arsenide ("GaAs") supply and the ramp-up of GaN production, and management targets delivering FY2027 in line with market expectations.

Disagree with this article?